Longeveron Inc. (LGVN)
After hours:
| Previous close | 26.26 |
| Open | 23.99 |
| Bid | 19.30 x 1800 |
| Ask | 19.56 x 900 |
| Day's range | 20.15 - 25.66 |
| 52-week range | 2.84 - 45.00 |
| Volume | |
| Avg. volume | 11,058,954 |
| Market cap | 390.634M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.75 |
| Earnings date | 14 May 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Longeveron Inc. Announces Pricing of a $20.5 Million Private Placement
MIAMI, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that it entered into a securities purchase agreement with certain institutional investors to purchase approximately $20.5 million worth of its common stock and warrants in a private placement. Under the terms of the securities purchase agreement, the Comp
- GlobeNewswire
Longeveron Announces Phase 2 Clinical Trial in Japan to Test Safety and Efficacy of Lomecel-B on Aging Frailty Patients
New trial is in collaboration with Japan’s National Center for Geriatrics and Gerontology (NCGG) and Juntendo University HospitalMIAMI, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain life-threatening conditions, announced today that it has entered into a sponsored clinical research agreement with the National Center for Geriatrics and Geron
- Motley Fool
Why Longeveron Stock Is Skyrocketing Today
Shares of Longeveron (NASDAQ: LGVN) were skyrocketing 72.9% as of 11:51 a.m. ET on Wednesday after more than doubling earlier in the day. An epic short squeeze appears to be underway. Longeveron announced on Nov. 18 that the U.S. Food and Drug Administration (FDA) granted a Rare Pediatric Disease designation to experimental drug Lomecel-B in treating a rare congenital heart defect.
